TheEdgeResearch
Home / Stocks / RZLT

Rezolute, Inc. (RZLT)

NASDAQ Healthcare Biotechnology
$3.92 ▼ -6.67%
Market Cap
$379.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.62
52-Wk Range
1.07-11.17
CEO
Nevan Charles Elam
Country
US
Currency
USD

Rezolute, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Redwood City, CA, US. The stock last traded at $3.92, down 6.67% on the session, giving a market capitalisation of $379.2M. On trailing twelve-month figures it carries a trailing P/E of -5.16, a net margin of 0.0%. Its beta of 0.62 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5.16
Price / Sales
0.00
Price / Book
4.78
EV / EBITDA
-4.65
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.01
Current ratio
9.92
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
63
IPO date
2013-01-14
Headquarters
Redwood City, CA, US
About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Comparable companies

Rezolute, Inc. is most often compared with the following Healthcare names:

PHARRARERLYBZVRA
More research on RZLT
RZLT technical analysis RZLT TheEdge Score Compare against peers
Open full interactive analysis & DCF →